JP2011502966A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502966A5
JP2011502966A5 JP2010531330A JP2010531330A JP2011502966A5 JP 2011502966 A5 JP2011502966 A5 JP 2011502966A5 JP 2010531330 A JP2010531330 A JP 2010531330A JP 2010531330 A JP2010531330 A JP 2010531330A JP 2011502966 A5 JP2011502966 A5 JP 2011502966A5
Authority
JP
Japan
Prior art keywords
dopamine transporter
patient
composition
ligand
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010531330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502966A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/081569 external-priority patent/WO2009058851A2/en
Publication of JP2011502966A publication Critical patent/JP2011502966A/ja
Publication of JP2011502966A5 publication Critical patent/JP2011502966A5/ja
Pending legal-status Critical Current

Links

JP2010531330A 2007-10-31 2008-10-29 ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法 Pending JP2011502966A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98419407P 2007-10-31 2007-10-31
PCT/US2008/081569 WO2009058851A2 (en) 2007-10-31 2008-10-29 Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level

Publications (2)

Publication Number Publication Date
JP2011502966A JP2011502966A (ja) 2011-01-27
JP2011502966A5 true JP2011502966A5 (cg-RX-API-DMAC10.html) 2012-11-15

Family

ID=40591729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010531330A Pending JP2011502966A (ja) 2007-10-31 2008-10-29 ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法

Country Status (5)

Country Link
US (2) US20100312105A1 (cg-RX-API-DMAC10.html)
EP (1) EP2211911A4 (cg-RX-API-DMAC10.html)
JP (1) JP2011502966A (cg-RX-API-DMAC10.html)
CA (1) CA2703563A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009058851A2 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540512A (ja) 2007-09-26 2010-12-24 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 異なるタイプの認知症を特異的に診断する方法
AU2014240105B2 (en) * 2013-03-15 2019-10-31 Cerora, Inc. Multi-modal pharmaco-diagnostic assessment of brain health
US10779747B2 (en) 2013-03-15 2020-09-22 Cerora, Inc. System and signatures for the multi-modal physiological stimulation and assessment of brain health
GB201313291D0 (en) * 2013-07-25 2013-09-11 Ge Healthcare Ltd Imaging neurological disease
CN104720840A (zh) * 2015-02-11 2015-06-24 清华大学深圳研究生院 基于多巴胺转运体显像特异性摄取比的半自动量化方法
WO2018148509A1 (en) * 2017-02-10 2018-08-16 Likeminds, Inc. Methods for in vivo monitoring of dopaminergic disorders and efficacy of treatment agents therefor
CN112805038A (zh) * 2018-07-18 2021-05-14 悦智有限公司 用于使化合物加速组织穿透到脑内的方法
CN113271985A (zh) * 2018-08-07 2021-08-17 悦智有限公司 用于诊断多巴胺能和运动障碍的方法
TWI686178B (zh) * 2019-10-09 2020-03-01 中原大學 自動化定位核子醫學腦部影像紋狀體與計算紋狀體專一性攝取率的方法與系統
WO2021092096A1 (en) * 2019-11-06 2021-05-14 Likeminds, Inc. Individualized dosing of radioactive tracers for imaging
WO2022240817A1 (en) * 2021-05-13 2022-11-17 Likeminds, Inc. Methods of visualizing dopamine transporters

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
JP2001517617A (ja) * 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
DE60124730T2 (de) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
MXPA05004828A (es) * 2002-11-07 2006-01-27 Applied Neurosolutions Inc Metodos para predecir si sujetos con deterioro cognoscitivo leve (mci) desarrollaran o no la enfermedad de alzheimer.
US20080302950A1 (en) * 2005-08-11 2008-12-11 The Brigham And Women's Hospital, Inc. System and Method for Performing Single Photon Emission Computed Tomography (Spect) with a Focal-Length Cone-Beam Collimation
US8150629B2 (en) * 2005-11-10 2012-04-03 In Silico Biosciences Method and apparatus for computer modeling of the interaction between and among cortical and subcortical areas in the human brain for the purpose of predicting the effect of drugs in psychiatric and cognitive diseases
ES2525932T3 (es) * 2006-05-02 2015-01-02 The Trustees Of The University Of Pennsylvania Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
JP2010540512A (ja) * 2007-09-26 2010-12-24 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 異なるタイプの認知症を特異的に診断する方法
US8084018B2 (en) * 2007-10-31 2011-12-27 Alseres Pharmaceuticals, Inc. Methods for imaging dopamine transporter level
US8557222B2 (en) * 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
HRP20150831T1 (hr) * 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
SG176628A1 (en) * 2009-06-05 2012-01-30 Link Medicine Corp Aminopyrrolidinone derivatives and uses thereof
GB0922304D0 (en) * 2009-12-22 2010-02-03 Ge Healthcare Ltd Radioiodinated compounds

Similar Documents

Publication Publication Date Title
Mueller et al. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study
JP5603855B2 (ja) 神経変成疾患の放射性薬剤による画像化
US20100312105A1 (en) Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
Zhu et al. PET/SPECT imaging agents for neurodegenerative diseases
Ossenkoppele et al. Longitudinal imaging of Alzheimer pathology using [11C] PIB,[18F] FDDNP and [18F] FDG PET
AU2019253837B2 (en) Imaging neurological disease
Henderson The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging
JP2014148529A (ja) ドーパミン輸送体レベルを造影するための方法
Villemagne et al. Amyloid imaging
Romano et al. Florbetapir F 18 for brain imaging of beta-amyloid plaques
US20210162078A1 (en) Method for diagnosis of dopaminergic and movement disorders
Kumar et al. Prospective Assessment of Alzheimer's Disease-Like Hypometabolism Pattern in the Brain of Diabetics in Contrast to Non-diabetics on Positron Emission Tomography-Computed Tomography Images Using Fluorodeoxyglucose in India
Chiotis Molecular imaging of tau in the pathological cascade of Alzheimer’s disease
Coakeley PET Imaging of Pathological Tau in Progressive Supranuclear Palsy
Ponto Positron Emission Tomography (PET) Imaging: Principles and Potential Role in Understanding Brain Function
Nair et al. Amyloid imaging
Justin et al. SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study
Ossenkoppele et al. Longitudinal Imaging of Alzheimer Pathology using [P
VLV et al. Regional variability of imaging biomarkers in autosomal dominant AlzheimerTs disease
JP2003503325A (ja) 注意欠陥多動性障害（ａｄ−ｈｄ）を決定するためのドーパミントランスポータの映像化